Impact of the Sustained Viral Response of Chronic Hepatitis c After Treatment With Direct Action Antivirals
NCT05062408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 321
Last updated 2021-11-17
Summary
The purpose of this study is to evaluate the evolution of liver injury with fibrosis data obtained using non-invasive serological markers in patients who achieved SVR after treatment with direct-acting antivirals.
Conditions
- Hepatitis C, Chronic
Sponsors & Collaborators
-
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
lead OTHER
Principal Investigators
-
Paula Fernández Álvarez · Hospital Universitario Virgen Macarena
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-03-01
- Primary Completion
- 2021-04-01
- Completion
- 2021-04-01
Countries
- Spain
Study Locations
More Related Trials
-
An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease
NCT02262728 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Monitoring of Hepatitis C Under DAA Therapy
NCT02904603 ·Status: UNKNOWN
-
Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
NCT02753699 ·Status: COMPLETED ·Phase: PHASE3
-
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
NCT00301509 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions
NCT02333292 ·Status: COMPLETED
-
Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients.
NCT00422838 ·Status: COMPLETED
-
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
NCT02349048 ·Status: COMPLETED ·Phase: PHASE2
-
Observational,Prospective Study to Develop and Validate a Prognostic Tool to Optimize Therapy in Patients With HCV G1/4
NCT01884402 ·Status: COMPLETED
-
A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants
NCT02268864 ·Status: COMPLETED ·Phase: PHASE2
-
Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions
NCT01908660 ·Status: COMPLETED
-
Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation
NCT02669940 ·Status: COMPLETED
-
Status of Chronic Liver Disease in Hepatitis C Virus (HCV) Patients Coinfected With Human Immunodeficiency Virus (HIV) in Andalusia
NCT02511496 ·Status: UNKNOWN
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
NCT03520660 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response
NCT00308048 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir
NCT02103699 ·Status: COMPLETED
-
Safety and Efficacy of Different Antiviral Regimens for Hepatitis C Virus Relapse
NCT04662138 ·Status: UNKNOWN
-
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
NCT02532907 ·Status: COMPLETED
-
Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis
NCT04112303 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of HCV-Infected Recent Injection Drug Users in U.S. Liver Clinics
NCT05895448 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection
NCT02250807 ·Status: COMPLETED ·Phase: PHASE3
-
Very Rapid and Rapid Virological Response as Predictors of Response of HCV Tretment
NCT03480269 ·Status: UNKNOWN
-
HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b
NCT01342003 ·Status: COMPLETED
-
Incidence of de Novo Hepatocellular Carcinoma After Antiviral Agents for HCV.
NCT03775798 ·Status: UNKNOWN
-
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Renally Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection
NCT02651194 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
NCT02642432 ·Status: COMPLETED ·Phase: PHASE3